380
Participants
Start Date
June 30, 2010
Primary Completion Date
October 31, 2012
Study Completion Date
April 30, 2015
0.5 mg of ranibizumab
Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
0.5 mg of ranibizumab + photodynamic therapy
Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
Sham injection
Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
Ural Institute of Cardiology, Yekaterinburg
De Haar Research Foundation, Rotterdam
Collaborators (1)
Ural Institute of Cardiology
OTHER
De Haar Research Foundation
OTHER
Ural State Medical University
OTHER